Cargando…

Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature

Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for...

Descripción completa

Detalles Bibliográficos
Autores principales: Mancuso, Alessandro, Pipitò, Luca, Rubino, Raffaella, Distefano, Salvatore Antonino, Mangione, Donatella, Cascio, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451286/
https://www.ncbi.nlm.nih.gov/pubmed/37627748
http://dx.doi.org/10.3390/antibiotics12081328
_version_ 1785095402020667392
author Mancuso, Alessandro
Pipitò, Luca
Rubino, Raffaella
Distefano, Salvatore Antonino
Mangione, Donatella
Cascio, Antonio
author_facet Mancuso, Alessandro
Pipitò, Luca
Rubino, Raffaella
Distefano, Salvatore Antonino
Mangione, Donatella
Cascio, Antonio
author_sort Mancuso, Alessandro
collection PubMed
description Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime–avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime–avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime–avibactam.
format Online
Article
Text
id pubmed-10451286
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104512862023-08-26 Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature Mancuso, Alessandro Pipitò, Luca Rubino, Raffaella Distefano, Salvatore Antonino Mangione, Donatella Cascio, Antonio Antibiotics (Basel) Case Report Bone and joint infections (BJIs) caused by multidrug-resistant gram-negative bacteria are becoming a concern due to limited therapeutic options. Although not approved for these indications, an ever-growing amount of evidence supports the efficacy and safety of ceftazidime–avibactam as a therapy for osteomyelitis and prosthetic joint infections. Here, we present three cases of difficult-to-treat resistant Pseudomonas aeruginosa osteomyelitis that were successfully treated with ceftazidime–avibactam alone or in combination therapy with fosfomycin and amikacin. Ceftazidime–avibactam was prescribed at a daily dose of 2.5 g every 8 h for 42 days in all cases. One potential drug-related adverse effect was observed, i.e., Clostridioides difficile infection, which occurred after fourteen days of treatment with ceftazidime–avibactam. MDPI 2023-08-17 /pmc/articles/PMC10451286/ /pubmed/37627748 http://dx.doi.org/10.3390/antibiotics12081328 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Mancuso, Alessandro
Pipitò, Luca
Rubino, Raffaella
Distefano, Salvatore Antonino
Mangione, Donatella
Cascio, Antonio
Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
title Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
title_full Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
title_fullStr Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
title_full_unstemmed Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
title_short Ceftazidime-Avibactam as Osteomyelitis Therapy: A Miniseries and Review of the Literature
title_sort ceftazidime-avibactam as osteomyelitis therapy: a miniseries and review of the literature
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10451286/
https://www.ncbi.nlm.nih.gov/pubmed/37627748
http://dx.doi.org/10.3390/antibiotics12081328
work_keys_str_mv AT mancusoalessandro ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature
AT pipitoluca ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature
AT rubinoraffaella ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature
AT distefanosalvatoreantonino ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature
AT mangionedonatella ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature
AT cascioantonio ceftazidimeavibactamasosteomyelitistherapyaminiseriesandreviewoftheliterature